In melanoma patients treated with combination anti-CTLA4 and anti-PD1 checkpoint blockade, an increase in CD21lo/neg B cells could be detected after the first cycle of immunotherapy and increases in CD21lo/neg B cells both preceded and correlated with frequency and severity of immune-related adverse events. This evidence concerns the gene CTLA4 and melanoma.